European Companies Search Engine
EU funding (€2,255,360): Protease‐guided tumor targeting tools to revolutionize cancer diagnosis and treatment. Hor23 Aug 2022 EU Research and Innovation programme "Horizon"
Overview
Text
Protease‐guided tumor targeting tools to revolutionize cancer diagnosis and treatment.
Europe has a high cancer burden: in 2020, 2.7 million EU citizens were diagnosed with the disease and 1.3 million lost their lives to it. This toll is expected to increase further, mainly because Europe's population is ageing: by 2035, cancer will be the leading cause of death in the EU. In 2021, the EC published its ‘Europe's Beating Cancer Plan’ (EBCP), calling for a big push in cancer research. Cancer diagnostics and therapeutics should rapidly become more effective and selective, patient-friendly and personalized. All these goals are directly addressed by developing better tumor targeting strategies. Typically, they consist of equipping diagnostics and therapeutics with a vector unit. The vector unit binds to a protein that is overexpressed on cancer cells or in the Tumor Micro-Environment (TME), causing the diagnostic or therapeutic payload to accumulate in the tumor. Over the last decades, huge effort has gone in approaches that use antibodies as vectors, but return-on-investment has overall been rather poor. Exciting, recent innovations rely on small molecule vectors that target TME proteases. Proteases are ideal candidates for tumor targeting: they are often strongly overexpressed in the TME and possess an active site that allows high-affinity anchoring of vectors. Members of this consortium have played a leading role in these developments. OncoProTools wants to force breakthroughs in cancer diagnosis and therapy by: 1) Exploring innovative venues for protease targeting in CAR T cell therapy. 2) Discovering novel vectors that bind to other TME proteases: cathepsins S, B, L and granzyme B 3) Personalize applications of protease targeting: deliver innovative diagnostics through deeper understanding of TME biology. At the same time, OncoProTools will deliver a training program that truly captures the MSCA values, to 10 Doctoral Candidates. They will be provided with all capabilities to become leaders of tomorrow's R&I in Europe.
Funded Companies:
| Company name | Funding amount |
| Alma Mater Studiorum - Universita Di Bologna | ? |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | €251,971 |
| Cellply Srl | €259,438 |
| CROMED KUTATO ES SZOLGALTATO KOZPONTOK kft. | €152,441 |
| Faculdade de Farmácia da Universidade de Lisboa | €243,403 |
| HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF e. V. | €260,539 |
| JOHANNES GUTENBERG-UNIVERSITAT MAINZ | €260,539 |
| Kobenhavns Universitet | €301,788 |
| Universiteit Antwerpen | €525,240 |
Source: https://cordis.europa.eu/project/id/101073231
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Alma Mater Studiorum - Universita' DI Bologna, Bologna, Italy.